AU2017249218B2 - Chiral peptides - Google Patents

Chiral peptides Download PDF

Info

Publication number
AU2017249218B2
AU2017249218B2 AU2017249218A AU2017249218A AU2017249218B2 AU 2017249218 B2 AU2017249218 B2 AU 2017249218B2 AU 2017249218 A AU2017249218 A AU 2017249218A AU 2017249218 A AU2017249218 A AU 2017249218A AU 2017249218 B2 AU2017249218 B2 AU 2017249218B2
Authority
AU
Australia
Prior art keywords
amino acid
phe
disease
orn
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017249218A
Other languages
English (en)
Other versions
AU2017249218A1 (en
Inventor
Andrew D. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcuate Therapeutics Inc
Original Assignee
Arcuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcuate Therapeutics Inc filed Critical Arcuate Therapeutics Inc
Publication of AU2017249218A1 publication Critical patent/AU2017249218A1/en
Application granted granted Critical
Publication of AU2017249218B2 publication Critical patent/AU2017249218B2/en
Assigned to ARCUATE THERAPEUTICS, INC. reassignment ARCUATE THERAPEUTICS, INC. Request for Assignment Assignors: CARNOT, LLC
Priority to AU2020260489A priority Critical patent/AU2020260489A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AU2017249218A 2016-04-11 2017-04-10 Chiral peptides Ceased AU2017249218B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020260489A AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321168P 2016-04-11 2016-04-11
US62/321,168 2016-04-11
PCT/US2017/026869 WO2017180535A1 (en) 2016-04-11 2017-04-10 Chiral peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020260489A Division AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Publications (2)

Publication Number Publication Date
AU2017249218A1 AU2017249218A1 (en) 2018-11-01
AU2017249218B2 true AU2017249218B2 (en) 2020-08-27

Family

ID=60042852

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017249218A Ceased AU2017249218B2 (en) 2016-04-11 2017-04-10 Chiral peptides
AU2020260489A Abandoned AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020260489A Abandoned AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Country Status (7)

Country Link
US (2) US10870678B2 (enExample)
EP (1) EP3442990A4 (enExample)
JP (1) JP2019523260A (enExample)
CN (1) CN109563131A (enExample)
AU (2) AU2017249218B2 (enExample)
CA (1) CA3020393A1 (enExample)
WO (1) WO2017180535A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7606966B2 (ja) 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ
KR20210093957A (ko) 2018-12-18 2021-07-28 스텔스 바이오테라퓨틱스 코포레이션 미토콘드리아-표적화 펩타이드
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
US20210255196A1 (en) * 2020-01-17 2021-08-19 Waters Technologies Corporation Low binding surfaces for peptide mapping
KR20220151628A (ko) * 2020-03-06 2022-11-15 알레그로 파마슈티칼스, 엘엘씨 미토콘드리아 기능의 손상을 개선하거나 감소시키기 위한 치료
AU2020454871A1 (en) 2020-06-25 2023-01-19 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
EP2197451A1 (en) 2007-06-07 2010-06-23 Institute For Hepatitis And Virus Research 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses
JP5697450B2 (ja) * 2007-10-02 2015-04-08 マリーナ バイオテック，インコーポレイテッド 核酸の送達のためのリポペプチド
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
JP5238297B2 (ja) 2008-03-04 2013-07-17 シャープ株式会社 認証方法および入力装置
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP3150215A1 (en) 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN102711785A (zh) 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP3100739A1 (en) 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN104725472A (zh) 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2011106717A1 (en) 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN105879008A (zh) 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3488941A1 (en) 2011-03-24 2019-05-29 Cornell University Aromatic-cationic peptides and uses of same
CN103764159A (zh) 2011-06-14 2014-04-30 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3078384A1 (en) 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
EP3170506B1 (en) 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2013155334A1 (en) 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6272853B2 (ja) * 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20140034183A1 (en) 2012-07-31 2014-02-06 Viz Enterprises, Llc Cap assembly for dispensing a dispensable component and method of making and using the same
MX2015005102A (es) 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
US20160193278A1 (en) 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160175379A1 (en) 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
EP3049096B1 (en) 2013-09-27 2018-12-12 Cornell University Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
JP2016539931A (ja) 2013-10-23 2016-12-22 株式会社カネカ テトラペプチド化合物及びその製造方法
EP3077049B1 (en) 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
CN112457368A (zh) 2013-12-27 2021-03-09 康德生物医疗技术公司 药学相关的芳香族阳离子肽
EP2913287B1 (en) 2014-02-26 2018-01-03 Otis Elevator Company Governor for controlling the speed of a hoisted object relative to a guide member
CA2942143A1 (en) 2014-03-03 2015-09-11 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides and methods of generating the same
WO2016004441A1 (en) 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chat R., B & Di Paulo G., "Knockout punch: cardiolipin oxidation in trauma", Nature Neuroscience, 2012. Vol. 15, No. 10, pp, 1325 - 1327 *

Also Published As

Publication number Publication date
EP3442990A4 (en) 2019-12-18
US10870678B2 (en) 2020-12-22
US20190153032A1 (en) 2019-05-23
JP2019523260A (ja) 2019-08-22
CA3020393A1 (en) 2017-10-19
CN109563131A (zh) 2019-04-02
US20200407395A1 (en) 2020-12-31
WO2017180535A1 (en) 2017-10-19
EP3442990A1 (en) 2019-02-20
AU2020260489A1 (en) 2020-11-26
AU2017249218A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
AU2017249218B2 (en) Chiral peptides
DE19544687A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TWI568447B (zh) 具有快速透皮速度的多肽及多肽相關化合物的前藥組合物
CN117624286A (zh) 线粒体靶向肽
TW201117826A (en) Fatty acid niacin conjugates and their uses
JP7082861B2 (ja) 新規な細胞透過性サクシネート化合物
CN102498094A (zh) 胍法辛的前药
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
AU2019403856B2 (en) Mitochondria-targeting peptides
KR20160067840A (ko) 펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
WO2003076391A2 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
EP1483285B1 (de) HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG
DE69908756T2 (de) Matrix-metalloproteinase-inhibitoren
JP2012530764A (ja) メキシレチンのアミノ酸およびペプチドプロドラッグ並びにその使用
CN101395143A (zh) 用于治疗疟疾或aids的氮杂杂环化合物
CN101511816B (zh) 具有改善的生物利用度的氨基异喹啉凝血酶抑制剂
WO2020214518A1 (en) Methods of treating renal conditions using peptides that improve mitochondrial function
US20070238671A1 (en) Isopeptide Gap Junction Modulators
HK1168602A (en) High penetration prodrug compositions of peptides and peptide-related compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ARCUATE THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): CARNOT, LLC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired